Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAIX-PET in Von Hippel-Lindau Disease
NCT07171905Phase 2Recruiting
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 89Zr-DFO-girentuximab in von Hippel–Lindau disease (VHL), sponsored by IRCCS Ospedale San Raffaele. Started Feb 2026; status: recruiting.
02
Drugs
89Zr-DFO-girentuximab
03
Conditions
von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT07171905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07171905.